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tazidune against inducible Gram-negative isolates, and comparable 
activity to ceftazldime against Pseudomom aeruginosa. 
Conclusion: Fourth generation cephalosporins are highly potent 
agents, but continued surveillance is mandatory. 
(s182j Antimicrobial surveillance programmes 
J.E Acar. Fondation H6pital SaintJoseph, Paris, France 
Currently, prevalence rates for nosocomial infections range between 
5% and 17% of patients adrmtted to hospitals. The control of noso- 
comial infections has been well recognised as a major priority in the 
hospital setting. Components for controhg nosocomial infections 
in the hospital indude antibiotics, which hold a rather ambivalent 
position: empirically used, antibiotics may select for resistant bac- 
teria. It is important to target the micro-organism and hmit the 
spread of resistant bacteria. Antimicrobial surveillance programmes 
are unique tools to detect and idennfy dangerous micro-organisms 
and to optimise the use of empiric antibiotic theram. A variety 
of surveillance programmes have been developed. Enhancements in 
surveillance have been related to improved sampling, accurate ch i -  
cal information, quantitative methods ofsusceptibility testing, quality 
control measures in the laboratory, as well as interpretation of the re- 
sults. The database of detailed mformation can be analysed with the 
appropriate software. The results can them be compared to mforma- 
tion gathered ate other institutions, on regional, national and global 
bases. 
1 S183 I Informed decisions in an era of resistance 
A.E Ehrhardt. Centerfor Research in Anti-Infectives G. Biotechnoloa, 
Creighton University, Omaha, hJE, USA 
Antimicrobial resistance is increasing worldwide. Recent increases 
in p-lactam resistance amongst Gram-negative bacteria such as En- 
teroborter cloacae, Citrobacter freundii, and Pseudomom aemginosa have 
been linked to use and overuse of ater-generation cephalosporins. 
Further resistance emergence may be delayed or reduced through 
the use of newer agents, combination therapy and antibiotic cychg. 
In vim data suggest that the fourth-generation cephalosporins are 
generally more potent than, and select less resistance than previ- 
ous agents. I n i d  clinical data, though yet sparse, suggest that sub- 
stitution of these agents for their predecessors, particularly when 
in combination with aminoglycosides, results in lower resistance 
rates. W e  clinical trials, due to their design, have shown drugs 
such as cefepime to be at least comparable to the third-generation 
cephalosporins, superiority of the fourth-generation agents is in- 
dicated in selected cases of infection with Bush group 1 en- 
zyme-producing bacteria. This superiority is at least partially due 
to the low inducing potential for the group 1 enzymes, rapid per- 
meation characteristics and resistance to hydrolysis. Organisms like 
E. cloacae can become resistant to thxd-generation agents through 
a single mutational step, while two mutations are required for re- 
sistance to the fourth-generation drugs. Adoption of practices and 
agents that reduce the selection of resistance may extend the use- 
ful lives of our current drugs, and may also delay the onset of the 
“post-antibiotic era”. 
S184 \ Empiric Therapy: Algorithms for Success 
J. Carlet. F 
No abstract available. 
I S185 I Management strategies for infection in the 
J. Klastersky. Department Oflntemal Medicine, ImtitutJuZes Bordet, 
BmsseL, Belgium 
neutropenic patient 
Neutropenic patients are susceptible to severe and prolonged infec- 
tion. Empiric therapy to prevent it has traditionally been designed 
to cover Gram-negative rods, especially P amginosa, which were the 
most likely bacterial pathogens. Over the past two decades however, 
Gram-positive infections have progressively become a more common 
cause of sepsis in neutropenic patients, now accounting for 70% of 
infections. Adequate coverage against Gram-negative organisms re- 
mains nevertheless mandatory. It is performed usually with a combi- 
nation ofantibiotics but recently introduced antibiotics like cefepime 
and meropenem have been used successfully as a monotherapy These 
agents have an excellent antipseudomal activity, they are synergis- 
tic with aminoglycosides and, moreover, are effective against many 
streptococci and methicillin-sensitive staphylococci. Vancomycin or 
teicoplanin are only indicated in the presence of a resistant organism, 
most commonly Staph. cpidermidis. The addition of amphotericin B 
is indicated after 96 hours if the patient remains neutropenic and 
febrile, and the initial microbiological workup has been negative. 
This is especially the case in patients with severe neutropenia and/or 
a newly apparent c h c a l  site of infection. The suspicion of fun- 
gal infections should be even higher in neutropenic patients who 
are immunosuppressed, such as those with graft-versus-host dwease 
after allogeneic bone marrow transplantation. In those patients, cy- 
tomegalovirus and other vital infections should be looked for and 
treated early Colony stimulating factors can effectively shorten the 
duration of neutropenia and can be used as an adjunct to antibacte- 
rial and antifungal agents when neutropenia is severe and the control 
of dection is not optimal. 
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Endotoxin Influences Endothelial Barrier 
Function 
S.E. Goldblum. VA Maryland Health Care System, University o j  
Maryland School of Medicine, Balfimore, Maryland, USA 
Gram-negative septic processes can be complicated by vascular leak 
syndromes, including the adult respiratory &tress syndrome. The 
bacterial component responsible for much of the endothelial cell 
(EC) injury and dysfunction is the bacterial lipopolysaccharide 
(LPS). Although LPS induces numerous host medators of EC in- 
jury, evidence also exists for a direct role for LPS. LPS, in concert 
with the accessory molecules LPS-bindmg protein (LBP) and soluble 
CD14, directly interacts with the vascular EC to induce loss of bar- 
rier function through the paracellular pathway. The molecular basis 
for this LPS-EC interaction and the resultant EC response have not 
been defined. A specific binding site/receptor for LPS on the non 
CD14-bearing EC, although implied, has not been demonstrated. 
We now know that LPS induces tyrosine phosphorylation of a cy- 
toskeletal protein, p&, and that protein p s i n e  kmase inhibition 
protects against opening of the EC paracellular pathway in response 
to LPS. The phosphopsine-containing proteins in LPS-exposed 
EC can be immunolocalized in part, to the intercellular boundaries. 
The LPS-induced endothelial barrier dysfunction also appean to 
be mediated through actin reorganization. LPS induces EC actin de- 
polymerization and prior F-actin stabilization with phallicidin pm- 
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tects against the loss of barrier function. The LPS-induced actin 
reorganization is also tyrosine phosphorylation-dependent. 
Conclusions: LPS directly influences endothelial barrier fUnc- 
tion through tyrosine phosphorylation-dependent actin reorganiza- 
tion and opening of the paracellular pathway. 
(51871 Effect of Bacterial Exotoxins on Endothelial 
W. Seeger. D 
Functions 
No abstract available. 
1 S188 I Microbial-Leukocyte-Endothelial Cell 
Interactions and Altered Penneabili of the 
Blood-Brain Barrier during Meningitis 
G.C. Townsend, WM. Scheld. University of Krg'nia School o j  
Medicine, Charfoffesville, VA, USA 
Bacterd meningitis (BM) is characterized by the presence of poly- 
morphonuclear neutrophils (PMNs) within the subarachnoid space. 
Evidence indicates that hgh cerebrospmal fluid concentrations of 
PMNS contribute significantly to the poor outcomes resulting from 
BM. Much of the research being conducted BM has focused on the 
identification of host factors that may contribute to this process. 
Interactions between bacteria, PMNs, and the cerebral microvas- 
cular endothelial cells (CMVECs) that comprise the blood-brain 
barrier likely play a sigmficant role in the generation of the host 
inflammatory response and in the development of the pathophysio- 
logic events that occur during BM. Exposure of CMVECs to certain 
bacterial components or to endogenous proinflammatory mediators 
stimulates production and release of factors that are chemotactic for 
and/or activate PMNs. Increased expression and avidity of leuko- 
cyte-endothelid cell adhesion molecules on PMNs and on CMVECs 
fadtate localization and transendothelial migration of PMNS. Bac- 
teria, PMNs, and their products may also have deleterious effects on 
CMVECs, thus compromising the integrity of the blood-brain bar- 
rier and the ability of the CMVECs to maintain homeostasis within 
the central nervous system. Advances in the understanding of these 
interactions may help to idenhfy targets to direct agents that may be 
used in the adjunctive therapy of BM. 
w] Endothelml Lesions in Malaria 
G.E. Grau. C H  
No abstract available. 
Influenza and pneumococcal vaccination for 
older adults in Western Europe 
[ s190 I The Epidemiology of Influenza and 
Pneumococcal Infections 
J. Henrichsen. Sfatens Serum Insfifuf, Copenhagen, Denmark 
Due to antigenic drifl influenza A and B viruses usually cause 
epidemics of influenza in Europe and elsewhere 5-6 times over 
a 10-year period. Antigenic shift in influenza A virus may cause 
changes that make most of the worlds population susceptible leading 
to influenza pandemics. This happened in 1900, 1918 ("The Span- 
ish flu"), 1957 (Asiatic flu), 1968 (Hong Kong flu) and possibly in 
1995. In Denmark with a population of little over 5 mio, influenza 
epidemics led to an excess mortality of 1400 in 1989190, of 2000 in 
1993/94 and of 2800 in 1995/96. So, obviously, there is much to be 
obtained by prevention. 
Over the last twenty years the number of cases of invasive pneu- 
mococcal disease has increased ten times in Denmark - as well as 
reportedly in Norway The incidence was 20 cases per 100,000 in- 
habitants in 1995 and the highest rates were seen in the very young 
(23/100,000) and in the elderly (55/100,000). The ten first types 
in order of kquency represented 65% of all isolates f b m  patients 
of all ages and as many as 85% of isolates from children with some 
variation as to whch types actually were the ten most common over 
the years. 
Types present in the currently available 23-dent pneumococcal 
polysaccharide vaccines over the last 20 years have covered ca. 90% 
of all invasive dlsease isolates in most countries and in all age groups. 
ml The Clinical Effectiveness, Cost-Effectiveness 
and Implementation of Influenza Vaccination 
R. Snacken. Insfifufefor Hygiene and Epidemiolon, Brussels, Belgium 
Several s t u d m  have shown that influenza vaccines prevent 60 to 90% 
of natural-occurring influenza virus infections in adults. Among the 
elderly, influenza vaccination prevents 30 to 60% of duenza-related 
hospitalizations, and 30 to 54% of all-causes mortality. Additional 
studies have shown that the cost-effectiveness of influenza vacci- 
nation exceeds that of h o s t  all other preventive, screening and 
treatment measures used in the care of older persons. In the Nether- 
lands, a recent cost-effectiveness study led public health authorities 
to m o w  their policy and to include age 265 years as an indication 
for influenza vaccination. Currently, only four Western European 
countries have influenza vaccination policies that target only at-risk 
persons. Not surprisingly, great ddferences s t i l l  exist among these 
countries in their use of influenza vaccine, in 1995 the number of 
doses distributed ranged fium 48 to 170 doses per 1000 total pop- 
ulation. The reasons underlymg the persistent variations in vaccine 
use remain poorly understood. With this in mind, the European 
Scientific Working group on Influenza (ESWI) has initiated sev- 
eral socioeconomic studies of influenza and undertaken surveys on 
surveillance and diagnostic methods, immunization rates, and ed- 
ucational programs for health care providers and the public. The 
goal of these studies is to improve the implementation of influenza 
immunization policies throughout Europe. 
I 3 9 2  I The Clinical Effectiveness, Cost Effectiveness 
and Implementation of Pneumococcal 
Vaccination 
A. Hall. London School of Hygiene G. Tropical Media'ne, UK 
Pneumococcal infections are a major cause of morbidity and mor- 
tatity in adults resulting in increased costs to the health care sector 
as well as to the individual. Clinical trials and observational s t u d m  
(both case control and retrospective cohort designs) have examined 
the e5cacy and dectiveness of vaccination in older individuals. 
Clinical trials have failed to show efficacy against pneumococcal 
pneumonia largely because of methodological problems or unrep- 
resentative sample populations. The observational studies however 
have shown a c h i d  effectiveness of 50 to 70% in preventing in- 
wive pneumococcal disease. Cost effechveness studies conducted in 
the United States and more recently in The Netherlands and Spain 
sugest suggest vaccination of older people (over 64 years) to prevent 
pneumococcal pneumonia would be worthwhile, and a recent study 
from the US has shown that vaccination to prevent pneumococcal 
